Other

Novo Nordisk A/s

Antyra Inc.

Soren Ostergaard

Vladimir Berezin

Elisabeth Bock

Peter Holme Jensen

Arne Holm

Lars Christian Ronn

Marianne Olsen

Flemming M Poulsen

Peter Madsen

Palle Jakobsen

Svend Havelund

Thomas Hoeg-Jensen

Per Balschmidt

Ib Jonassen

Jan Markussen

Svend Ludvigsen

Anders Klarskov Petersen

Jane Spetzler

Niels Christian Kaarsholm

Helle Birk Olsen

Dorte Bjerre Steensgaard

Lauge Schaffer

Vladislav Soroka

Igor Ralets

Signe Ridderberg

Renuta Pillutla

Neil L Goldstein

Paul Fletcher

Ida Heise Stenfeldt Mathiasen

The present invention relates to novel ligands for the HisZnsites of the R-state insulin hexamer having the formula A-B-C-D-X (III), wherein: A is a chemical group which reversibly binds to a HisZnsites of an insulin hexamer; B is a linker; C is a fragment consisting of 0 to 5 neutral amino acids; D is a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups; and X is &#x2014;OH, &#x2014;NHor a diamino group. The present invention also relates to R-state insulin hexamers comprising such ligands, and aqueous insulin preparations comprising such R-state insulin hexamers.

[object Object]

The invention provides novel compounds which are capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM). Additionally, the invention relates to methods for treatment of normal, degenerated and damaged NCAM presenting cells.

NCAM binding compounds

Insulin derivatives having a built-in glucose sensor, capable of delivering insulin from a depot as a function of the glucose concentration in the surrounding medium (e.g. tissue), such that the rate of insulin release from the depot increases with an increased glucose concentration and decreases with a decreased glucose concentration.

Glucose dependent release of insulin from glucose sensing insulin derivatives

The invention provides novel compounds which are capable to stimulate the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM). Additionally, the invention relates to pharmaceutical compositions, medicaments and methods for treatment of normal, degenerated and damaged NCAM presenting cells.

Growing community of inventors

Bronshoj, Denmark

Soren Ostergaard